CD8A and cancer: CD27+IFNγ+ γδ T cells that express Vγ1 or Vγ4 TCR chains have anti-tumor properties capable of direct cancer cell killing and boosting CD8+ T cell cytotoxic responses (Chen et al., 2019; Dadi et al., 2016; Gao et al., 2003; He et al., 2010; Lança et al., 2013; Liu et al., 2008; Lopes et al., 2021; Reis et al., 2022; Riond et al., 2009; Street et al., 2004).